|
 Clinical study – Beijing, China
July 2004 – October 2004
CMO plus MSM (30 capsules)
20 patients (20 patients OA osteoarthritis)
Results: 75% effective OA
Clinical study – Shanghai, China
April 2001– August 2001
7 hospitals in Shanghai area
CMO plus sea cucumber extract (30 capsules)
120 patients, (30 patients RA rheumatoid arthritis, 90 patients OA)
Results 80% effective
Clinical study – Guangzhou, China
November 2000 – March 2001
CMO plus sea cucumber extract (30 capsules)
54 patients (25 patients RA, 29 patients OA)
Results: 70% effective RA
Results: 90% effective OA
Dosage study – China
2000 - 2005
Widespread dosage study
9000 patients (60% patients OA, 35% patients RA, 5% AS)
CMO plus sea cucumber extract or glucosamine (30 capsules)
30-60 capsules have a beneficial effect
OA 150-200 capsules
RA 300-400 capsules
AS 300+ capsules
Dr. Sands worked hard to create a
custom formula for the Chinese market that met the needs of both the
consumers and marketers. As you can see by the study results, he succeeded
in creating a very effective CMO formula named Joint Support.
When Dr. Sands flew to Florida to
meet with the delegation from China, the executives from Grandstone
Corporation and the product specialists from CMO Distribution Centers of
America, he had no idea that he was about to introduce a new word to the
Chinese language. When describing how CMO worked he coined the term
“immunomodulator” to summarize the overall effect of CMO on the immune
system. Later, during registration in China the term immunomodulator was
accepted as the descriptive action for CMO on the approval papers.
 Double blind clinical study –
Seoul, South Korea
May 2002 - February 2003
Seoul University study
80 patients (80 RA)
CMO plus glucosamine (60 capsules)
Results 80% effective
Empirical results from this double
blind study show a high success ratio of 80% in curing rheumatoid arthritis.
The summary and comments about this study are written by a very notable
Korean doctor. These impressive results and its notable constituents have
inspired widespread use in the Korean market where this CMO formula is named
BTE.
 Clinical study – Oklahoma,
United States
February 1999 - August 1999
McDade Foundation (Dr. McDade, Director)
21 patients
CMO standard formula (60 capsules)
Results 95% effective
Dr. Larry McDade was the first to use pH-balancing calcium prior to CMO
administration. Many doctors use coral calcium although Dr. McDade developed
a more refined method for pH balancing. At the time he first started this
technique, his improved success ratio was notable and the product specialist
from CMO Distribution Centers of America met with Dr. Sands and his team
seeking answers.
It was a lengthy meeting with some
rather interesting conclusions. Those conclusions were that CMO is a fatty
acid that breaks down in the alkaline environment of the duodenum. The pH
balance of the digestive tract can have a direct effect on the success of
breaking down and absorbing the CMO fatty acids. Effectively, Dr. McDade was
using the pH balancing to improve the absorption rate of CMO.
Further covered in that meeting was
the wide variety of successful diets and protocols created by so many
different health practitioners. All diet changes can affect the pH of the
digestive tract. This explains why the wide varieties of diets have success
in common, they all affected the pH level of the patient.
Although this method of pH balancing
is not the published standard use practice from the CMO manufacturer, it is
becoming more common among healthcare practitioners. Commonly they use a pH
balancing calcium such as coral calcium for 30 days prior to starting the
CMO.
Clinical study – San Diego,
United States
December 1995 – June 1996
San Diego Clinic, Dr. Sands
48 patients
CMO standard formula (100 capsules)
Results 96% effective
This study was conducted by the San
Diego Clinic where Dr. Sands is the medical director. The full details of
this study are available later in another chapter of this book.
Other studies
As Dr. Sands’ family explored the vast quantity of research information
and files he compiled, they discovered he corresponded with thousands of
doctors, clinics and academic institutions around the world. He exchanged
ideas with the leading autoimmune and cancer researchers in the
international medical community. It is no wonder so much unpublished
information was found in his files. Many studies, surveys and interesting
cases involving CMO were discovered. Two such notable studies were in Canada
and Poland.
 Double blind clinical study –
Poland
382 patients
Dr. H. Siemandi
Results 72% effective
Dr. Siemandi, who conducted the study in Poland, and Dr. Munoz, who wrote
the forward to this book, studied medicine together. Dr. Siemandi practices
medicine and is research administrator at a hospital in Baja, California and
Poland. This was the first study conducted other than the San Diego Clinic
study.
 Clinical study – Canada
1814 patients
Dr. R. Allen
Results 87% effective
Exploring the files further revealed
a series of faxes from Dr. Allen who directed the Canadian study of CMO.
Those correspondences were in regard to a custom CMO formula that had been
created for the Canadian market named Imunal that included 10 mgs of
manganese. s
The development stages of CMO took
many forms and formulas before the first public release in December of 1995
and the latest formulas available now. Despite the many variations in
formulas and treatment protocols, CMO has constantly proved an effective
cure for arthritis no matter what other ingredients are added or how it was
being used. It is a comfort to know that Dr. Sands’ discovery is not just
the only known cure for arthritis but, that it is also very effective and
has been well studied by the international medical community. |
